Menu
Search
|

Menu

Close
X

Adamas Pharmaceuticals Inc ADMS.OQ (NASDAQ Stock Exchange Global Market)

6.00 USD
+0.00 (+0.00%)
As of Jul 22
Previous Close 6.00
Open 6.00
Volume 95,923
3m Avg Volume 104,501
Today’s High 6.06
Today’s Low 5.91
52 Week High 29.45
52 Week Low 4.21
Shares Outstanding (mil) 22.51
Market Capitalization (mil) 520.30
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 10 analysts

KEY STATS

Revenue (mm, USD)
FY19
12
FY18
34
FY17
1
FY16
1
EPS (USD)
FY19
-1.080
FY18
-4.881
FY17
-3.956
FY16
-2.766
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.67
Price to Sales (TTM)
vs sector
2,939.55
7.92
Price to Book (MRQ)
vs sector
5.00
5.39
Price to Cash Flow (TTM)
vs sector
--
24.37
Total Debt to Equity (MRQ)
vs sector
32.50
14.56
LT Debt to Equity (MRQ)
vs sector
32.50
10.21
Return on Investment (TTM)
vs sector
-44.88
14.49
Return on Equity (TTM)
vs sector
-51.05
15.79

EXECUTIVE LEADERSHIP

Gregory Went
Chairman of the Board, Chief Executive Officer, Co-Founder, Since 2000
Salary: $550,000.00
Bonus: $260,200.00
Alfred Merriweather
Chief Financial Officer, Since 2017
Salary: $420,000.00
Bonus: $180,600.00
Christopher Prentiss
Chief Accounting Officer, Since 2017
Salary: --
Bonus: --
Jennifer Rhodes
Chief Compliance Officer, General Counsel, Corporate Secretary, Chief Business Officer, Since 2016
Salary: $246,311.00
Bonus: $82,215.00
Rajiv Patni
Chief Medical Officer, Since 2015
Salary: $424,000.00
Bonus: $200,600.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1900 Powell St Ste 1000
EMERYVILLE   CA   94608-1839

Phone: +1510.4503554

Adamas Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues. It has developed a portfolio of chrono-synchronous therapies to address chronic neurologic disorders. Its first product candidate is ADS-5102, a chrono-synchronous amantadine therapy, for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD). It has completed Phase II proof-of-concept study of ADS-5102 in these patients. Its Phase III clinical program included three placebo-controlled trials: EASED, EASE LID and EASE LID 3. Its second product candidate is ADS-4101, an extended-release version of single-agent compound for the treatment of epilepsy (partial onset seizures).

SPONSORED STORIES